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ABSTRACT 
 
Risk assessment of hepatitis B virus-related hepatocellular 
carcinoma development using liver stiffness measurement 
(FibroScan®) 
 
Kyu Sik Jung  
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Kwang-Hyub Han) 
 
Background/ Aims: Liver stiffness measurement (LSM) using FibroScan® 
accurately assesses the degree of liver fibrosis and the risk of hepatocellular 
carcinoma (HCC) development in patients with chronic hepatitis C (CHC). This 
study investigated the usefulness of LSM as a predictor of HCC development in 
patients with chronic hepatitis B (CHB). 
 
Methods: A total of 1,130 patients with non-biopsy proven CHB who 
underwent LSM between May 2005 and December 2007 were enrolled in this 
prospective study. After LSM was performed, patients attended regular 
follow-up as part of a surveillance program for the detection of HCC. 
 
Results: The mean age of the patients (767 men, 363 women) was 50.2 years 
and the median LSM was 7.7 kPa. Six hundred seventy two (59.5%) patients 
received antiviral treatment before or after enrollment. During the follow-up 
period (median, 30.7 months; range 24.0-50.9 months), HCC developed in 57 
patients (2.0% per 1 person-year). The 1, 2, and 3-year cumulative incidence 
rates of HCC were 0.80%, 3.26%, and 5.98%, respectively. On multivariate 
analysis, together with old age, male gender, heavy alcohol consumption (> 80 
g/day), serum albumin, and hepatitis B e antigen positivity, patients with a 
2 
higher LSM value were at a significantly greater risk of HCC development, 
with a hazard ratio of 3.07 [95% CI, 1.01–9.31; P=0.047] when LSM value 
8.1–13 kPa, 4.68 [95% CI, 1.40–15.64; P=0.012] when LSM value 13.1–18 kPa, 
5.55 [95% CI, 1.53–20.04; P=0.009] when LSM value 18.1–23 kPa, and 6.60 
[95% CI, 1.83–23.84; P=0.004] when LSM value >23 kPa, as compared to LSM 
value ≤8 kPa. 
 
Conclusion: Our data suggest that LSM could be a useful predictor of HCC 
development in patients with CHB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words : Chronic hepatitis B - Fibroscan – Hepatitis B virus – 
Hepatocellular carcinoma - Liver stiffness measurement - Transient 
elastography 
 
3 
Risk assessment of hepatitis B virus-related hepatocellular 
carcinoma development using liver stiffness measurement 
(FibroScan®) 
 
Kyu Sik Jung  
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Kwang-Hyub Han) 
 
 
I. INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors 
in the world. As the incidence of HCC is increasing, it is becoming a major 
public health problem.1 Unless HCC is diagnosed at an early stage, poor 
prognosis is expected due to limited treatment options.2 Thus, early detection of 
HCC is important for high-risk patients, such as those with chronic hepatitis B 
(CHB) and hepatitis C (CHC) infections or non-viral cirrhosis, and those 
exposed to environmental toxins.3 In particular, in patients with CHB and CHC, 
advanced liver fibrosis and cirrhosis are significantly correlated with the risk of 
HCC development.4,5 Therefore, reliable methods for the early identification of 
liver fibrosis progression and compensated liver cirrhosis are an essential part of 
an efficient surveillance program for the detection of HCC.6 
To date, liver biopsy (LB) had been the gold standard for assessing the 
severity of liver fibrosis and cirrhosis.7 Although LB is generally accepted to be 
a safe procedure, it can cause discomfort and carries a small risk of severe 
complications.8 Furthermore, LB is prone to sampling error as only 1/50,000 of 
the liver is analyzed microscopically.9 In addition, LB is not a suitable method 
for assessing the degree of liver fibrosis in a sequential manner only for the 
purpose of evaluating the risk of HCC development. 
4 
Recently, liver stiffness measurement (LSM) using FibroScan® has been 
introduced; it has proven clinical accuracy for the detection of liver fibrosis and 
cirrhosis and provided reproducible and reliable results.10,11 Furthermore, LSM 
can be expressed numerically as continuous variables, which allow clinicians to 
grade the degree of liver cirrhosis and assess the risks of developing 
liver-related complications. Because of these advantages, the role of LSM is 
now being extended as a predictor of HCC development in patients with chronic 
liver disease (CLD). Masuzaki et al. identified an association between LSM and 
the presence of HCC in patients with CHC in a cross-sectional study and they 
showed that LSM could be used as a predictive tool for HCC development in 
patients with CHC in a follow-up prospective study.12,13  
In previous cross-sectional studies, we reported different LSM values in 
patients having CHB with and without HCC.14,15 However, prospective studies 
investigating the role of LSM as a predictor of HCC development in patients 
with CHB are limited. In this study, we evaluated the usefulness of LSM for 
assessing the risk of HCC development in a large cohort of patients with CHB. 
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II. MATERIALS AND METHODS 
 
1. Patients 
 
From May 2005 to December 2007, a total of 1,229 patients with CHB visited 
the liver unit of Shinchon Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea. CHB was defined as persistent presence of serum 
hepatitis B virus surface antigen (HBsAg) for more than 6 months. Patients who 
provided informed consent received LSM and were consecutively enrolled in 
this prospective study. 
With our exclusion criteria (Figure 1),16-19 99 patients were excluded and 
the remained 1,130 patients were selected for statistical analysis. Twenty five 
patients who were excluded due to LSM failure (n=8) or an invalid LSM (n=17) 
had significantly higher body mass index than the other patients (28.5 vs. 23.7 
kg/m2, P<0.001), whereas the other variables did not differ significantly (all 
P>0.05, data not shown). 
On the same day as LSM, blood parameters including serum albumin, total 
bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
prothrombin time, platelet count, and alpha-fetoprotein (AFP) were recorded. 
HBsAg and hepatitis B e antigen (HBeAg) were measured using standard 
enzyme-linked immunosorbent assays (Abbott Diagnostics, Abbott Park, IL, 
USA). HBV DNA levels were assessed with a hybridization capture assay 
(Digene Diagnostics, Gaithersburg, MD, USA) having a detection limit of 
141,000 copies/mL. 
If histologic information was not available, clinically diagnosed liver 
cirrhosis (cLC) was defined as followings: 1) the patients had a platelet count 
<100,000/uL and ultrasonographic findings suggestive of cirrhosis including a 
blunted, nodular liver edge accompanied by splenomegaly (>12 cm), 2) 
esophageal or gastric varices existed, or 3) overt complications of liver cirrhosis 
6 
were observed, including ascites, variceal bleeding, and hepatic 
encephalopathy.20,21 The study protocol conformed to the ethical guidelines of 
the 1975 Helsinki Declaration and was approved by the institutional review 
board of our institute. 
 
Figure 1. The recruitment algorithm. 
 
 
2. Follow-up  
 
Each patient was screened for HCC with ultrasonography at their initial visit. 
Two patients were excluded due to presence of HCC at initial visit. If no 
evidence of HCC was detected, patients were followed up with AFP and 
ultrasonography every 3 or 6 months. During the surveillance, HCC was 
diagnosed based on the guideline of American Association for the Study of 
Liver Diseases.2 Briefly, patients were diagnosed with HCC if they had a tumor 
with a maximum diameter of >2 cm and the typical features of HCC on 
dynamic computed tomography (CT) (defined as hyperattenuation in the arterial 
phase and early washout in the portal phase), and an AFP >200 ng/ml.2 If the 
maximum diameter of tumor was 1 to 2 cm, dynamic CT and magnetic 
7 
resonance imaging were performed. HCC was diagnosed if coincidental typical 
features of HCC were noted. If the tumor did not satisfy above criteria, a biopsy 
was performed. When the tumor was <1 cm, ultrasonography was repeated after 
3 months. The last follow-up date in this study was December 2009. 
 
3. Liver stiffness measurement 
 
LSM was performed on the right lobe of the liver through the intercostal spaces 
on patients lying in the dorsal decubitus position with the right arm in maximal 
abduction.16 The operator located a liver portion that was at least 6 cm thick and 
free of large vascular structures, and pressed the probe button to commence the 
measurement. Only one experienced technician (more than 1,000 examinations) 
blind to the clinical data of patients, was allowed to perform LSM. The results 
are expressed as kilopascals (kPa). In this study, only LSM examinations with at 
least 10 validated measurements and a success rate of at least 60% were 
considered reliable. The median value of successful measurements was selected 
as a representative of the LSM value in a given patient only if an interquartile 
range to median value ratio was less than 0.3. Any LSM value that did not 
satisfy the above conditions was considered unreliable and excluded from 
further analysis. 
 
4. Cutoff values for liver cirrhosis and stratification interval 
 
Initially, we adopted 13 kPa as the cutoff value for liver cirrhosis based on a 
previous meta-analysis22. Then, we adopted the same stratification interval (5 
kPa) as a Japanese study with CHC12 to stratify patients with LSM value >13 
kPa, because we planned to compare the risk of HCC development between 
CHB and CHC. However, given that almost 80% of the study population 
(n=888) had LSM value ≤13 kPa, we extended our stratification below the 
8 
cutoff of liver cirrhosis by same interval. Ultimately, our study population was 
stratified into five groups as ≤8 kPa, 8.1–13 kPa, 13.1–18 kPa, 18.1–23 kPa, 
and >23 kPa. 
 
4. Statistical analysis  
 
Data are expressed as the means ± standard deviation, median (range), or n (%) 
as appropriate. When comparing the baseline characteristics of patients with and 
without HCC development and those with and without cLC, the chi-square test 
and Fisher’s exact test were used for categorical data, and Student’s t-test and 
the Mann-Whitney U test were used for continuous variables. The annual 
incidence rates of HCC were expressed as the person-year method. The 
cumulative incidence rates of HCC were calculated using the Kaplan-Meier 
method. The proportions of patients with HCC development and cLC according 
to LSM stratification were compared with Mantel-Haenszel tests. The incidence 
of HCC according to LSM change was compared using the chi-square test 
(Fisher's exact test) with the Bonferroni correction. To estimate independent 
risk factors for HCC development, univariate and subsequent multivariate Cox 
proportional hazard regression analysis were used. Hazard ratios and 
corresponding 95% confidence interval (CI) are indicated. A P-value <0.05 on 
two-tailed test was considered significant. Data analysis was performed using 
the SAS program (9.1ver, SAS Inc, North Carolina). 
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III. RESULTS 
 
1. Baseline characteristics 
 
The baseline characteristics of 1,130 patients at enrollment are summarized in 
Table 1. The mean age of our study population (767 men and 363 women) was 
50.2 years. One hundred ninety-seven (17.4%) patients had cLC (178 patients 
with thrombocytopenia (<100,000/uL) and ultrasonographic findings suggestive 
of cirrhosis, nine with esophageal or gastric varices, one with overt 
complication of cirrhosis, and nine with more than two positive findings for 
cirrhosis) and most of them (n=185, 93.9%) belonged to Child-Turcotte-Pugh 
class A. The baseline characteristics of the patients with cLC were compared to 
those without (Table 2). At enrollment, 444 (39.3%) patients had a previous or 
an ongoing use of an antiviral agent (lamivudine [n=306], adefovir [n=114], 
entecavir [n=14], and combination of lamivudine and adefovir [n=10]), whereas 
228 (20.2%) patients received antiviral treatment after enrollment (lamivudine 
[n=98], adefovir [n=15], and entecavir [n=115]). The median LSM value was 
7.7 kPa (range 2.9-75 kPa).  
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Table 1. Baseline Characteristics (n = 1,130) 
Variables  
Demographic data 
Age (years) 50.2 ± 9.9 (21-81) 
Male 767 (67.9) 
Alcohol consumption >80 g/day 59 (5.2) 
Clinically diagnosed liver cirrhosis 197 (17.4) 
Diabetes mellitus 41 (3.6) 
Previous or ongoing antiviral treatment 
at enrollment 
444 (39.3) 
Body mass index (kg/m2)  
  Underweight (<18.5) 32 (2.8) 
  Normal (18.5-25) 752 (66.5) 
  Overweight (25.1-30) 325 (28.8) 
  Obesity (>30) 21 (1.9) 
Laboratory results  
Serum albumin (g/dL) 4.5 ± 0.4 (2.4-6.3) 
Total bilirubin (mg/dL) 0.9 ± 0.7 (0.2-4.8) 
Aspartate aminotransferase (IU/L) 33.8 ± 18.2 (4-167) 
Alanine aminotransferase (IU/L) 38.8 ± 27.2 (6-176) 
Prothrombin time (%) 92.1 ± 12.0 (35.2-100) 
Platelet count (109/L) 162.4 ± 64.1 (26-526) 
Alpha-fetoprotein (ng/mL) 3.07 (0.5-147) 
HBeAg positivity 408 (36.1) 
Detectable HBV-DNA† 361 (31.9) 
Liver stiffness measurement   
Liver stiffness measurement value (kPa) 7.7 (2.9-75) 
Interquartile range (kPa) 1.7 ± 2.4 (0.1-9.7) 
Success rate (%) 95.6 ± 8.3 (65-100) 
Variables are expressed as mean ± SD, median (range), or n (%).  
Lower limit of detectable HBV-DNA† was 141,000 copies/mL. 
HBeAg, hepatitis B e antigen; kPa, kilopascal.  
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2. The Incidence, Stage, and Treatment of HCC 
 
The median follow-up period was 30.7 months (range 24.0–50.9 months) 
constituting 2,885 person-years overall. HCC developed in 57 patients (2.0% 
per 1 person-year) during the study period. The cumulative incidence rates of 
HCC at 1, 2, and 3 years were 0.80%, 3.26%, and 5.98%, respectively. No 
significant difference existed in the duration of follow-up between patients with 
HCC development and those without (31.5 vs. 29.5 months, P=0.126). 
According to the staging system of Liver Cancer Study Group of Japan23, 33 
(57.9%) patients belonged to stage I, 16 (28.1%) to stage II, and 8 (14.0%) to 
stage III. Hepatic resection was done for 42 (73.7%) patients and 
radiofrequency ablation for 5 (8.8%) with curative aims. Palliative treatments 
including transarterial chemoembolization (n=6, 10.5%) and intra-arterial 
chemotherapy (n=4, 7.0%) were also performed.24 HCC was confirmed 
histologically in 42 patients with hepatic resection. 
 
3. Comparison between patients with HCC development and those without 
 
The clinical characteristics at enrollment between patients with HCC 
development and those without are compared in Table 2. Age, the proportion of 
males, heavy alcohol consumption (>80 g/day), the proportions of cLC and 
diabetes mellitus, AST, AFP, HBeAg positivity, and LSM value were 
significantly higher among patients with HCC development, whereas serum 
albumin, prothrombin time, and platelet count were significantly higher among 
those without (all P<0.05). Among the 57 patients with HCC, esophageal or 
gastric varices were found at enrollment in eight (14.0%) patients and no other 
liver-related complication was found at enrollment.  
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4. Risk Analysis of HCC Development According to LSM value 
 
The proportion of patients with cLC at enrollment and HCC development were 
significantly greater in the groups with higher LSM value (Mantel-Haenszel 
tests, P<0.001, Figure 2). In the univariate analysis and subsequent multivariate 
analysis, together with older age, male gender, heavy alcohol consumption (>80 
g/day), lower serum albumin level, and HBeAg positivity, higher LSM values 
were at a significantly greater risk of HCC development, with a hazard ratio of 
3.07 [95% CI, 1.01–9.31; P=0.047] when LSM value 8.1–13 kPa, 4.68 [95% CI, 
1.40–15.64; P=0.012] when LSM value 13.1–18 kPa, 5.55 [95% CI, 
1.53–20.04; P=0.009] when LSM value 18.1–23 kPa, and 6.60 [95% CI, 
1.83–23.84; P=0.004] when LSM value >23 kPa, as compared to LSM value ≤8 
kPa (Table 3). 
The cumulative incidence rates of HCC increased significantly in 
association with elevated LSM value among the 5 stratified groups (log-rank 
test, P<0.001; Figure 3). The cumulative incidence rates at 1, 2, and 3 years 
were 0.17%, 1.12%, and 1.58% in patients with LSM value ≤8 kPa (0.54% per 
1 person-year); 1.05%, 2.51%, and 6.28% in patients with 8 kPa< LSM value 
≤13 kPa (1.75% per 1 person-year); 2.33%, 5.63%, and 8.77% in patients with 
13kPa< LSM value ≤18 kPa (2.94 % per 1 person-year); 0%, 7.86%, and 
19.07% in patients with 18 kPa< LSM value ≤23 kPa (7.04% per 1 
person-year); 4.48%, 16.8%, and 24.76% in patients with 23 kPa> LSM value 
(9.80% per 1 person-year).  
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Table 3. Univariate and Multivariate Cox Proportional Hazard 
Regression Analysis to Identify Independent Risk Factors for HCC 
Development 
Variables 
Univariate Multivariate 
P value Hazard ratio (95% 
CI) 
P value 
Demographic data    
Age <0.001 1.06 (1.02-1.09) <0.001 
Male 0.015 3.70 (1.62-8.44) 0.002 
Alcohol consumption 
>80g/day 
<0.001 2.30 (1.02-5.20) 0.040 
Clinically diagnosed liver 
cirrhosis 
<0.001 - - 
Diabetes mellitus <0.001 - - 
Previous or ongoing antiviral 
treatment at enrollment 
0.106 - - 
Body mass index  - - 
 Underweight     
 Normal  0.978   
 Overweight  0.981   
 Obesity 0.514   
Laboratory data    
Serum albumin <0.001 0.43 (0.23-0.83) 0.012 
Total bilirubin 0.497 - - 
Aspartate aminotransferase <0.001 - - 
Alanine aminotransferase 0.998 - - 
Prothrombin time  <0.001 - - 
Platelet count <0.001 - - 
Alpha-fetoprotein <0.001 - - 
HBeAg positivity 0.019 2.10 (1.02-5.21) 0.012 
Detectable HBV-DNA† 0.078 - - 
Liver stiffness measurement    
≤ 8 kPa  1 (reference)  
8.1-13 kPa <0.001 3.07 (1.01-9.31) 0.047 
13.1-18 kPa <0.001 4.68 (1.40-15.64) 0.012 
18.1-23 kPa <0.001 5.55 (1.53-20.04) 0.009 
> 23 kPa <0.001 6.60 (1.83-23.84) 0.004 
Lower limit of detectable HBV-DNA† was 141,000 copies/mL. 
HCC, hepatocellular carcinoma; CI, confidence interval; HBeAg, hepatitis B e 
antigen; kPa, kilopascal. 
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Figure 2. The proportion of patients with clinically diagnosed liver cirrhosis at 
enrollment and HCC development based on stratified LSM values. 
 
 
Figure 3. Cumulative incidence rates of HCC based on stratified LSM values 
(Kaplan-Meier plot). 
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5. Discordance in the diagnosis of cirrhosis by LSM and clinical criteria  
 
We investigated the discordance that could occur when diagnosing cirrhosis 
using LSM and clinical criteria, and evaluated any differences in the risk of 
HCC development. For this sub-analysis, we assessed 1,110 patients without 
baseline liver histology at enrollment (Figure 4).22 Overall, 874 (78.7%) 
patients showed LSM value ≤13 kPa and 236 (21.3%) showed LSM value >13 
kPa. In patients with LSM value ≤13 kPa, the incidence of HCC estimated by 
person-years method was not significantly different between patients with cLC 
(n=45, 5.1%) and those without (n=829, 94.9%) (0.87% vs. 0.89% per 1 
person-year, P=0.518). By contrast, among patients with LSM >13 kPa, HCC 
developed more frequently when liver cirrhosis was diagnosed according to 
clinical criteria (n=132, 55.9%) than when it was not (n=104, 44.1%) (5.84% vs. 
3.26% per 1 person-year, P<0.001).  
One hundred forty nine (13.4%) patients showed discordance in the 
diagnosis of cirrhosis when comparing LSM and clinical criteria. The incidence 
of HCC was higher in 104 patients who showed LSM >13 kPa and no cLC than 
45 who showed LSM ≤13 kPa with cLC (3.26% vs. 0.87% per 1 person-year) 
(Figure 4). 
 
6. Risk Analysis of HCC Development According to LSM change 
 
After excluding two patients who underwent follow-up LSM after HCC 
development, 822 patients underwent a second LSM after a median of 18.2 
months (range, 11.9–23.0 months) and HCC developed in 26 (3.2%) patients. 
To estimate the incidence of HCC according to the LSM change, we stratified 
the patients into four groups as follows: both initial and follow up LSM value 
≤13 kPa (Group 1), initial LSM value >13 kPa and follow up LSM value ≤13 
kPa (Group 2), initial LSM value ≤13 kPa and follow up LSM value >13 kPa 
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(Group 3), and both an initial and follow up LSM value >13 kPa (Group 4) 
(Figure 5). In patients with initial LSM value ≤13 kPa (Groups 1 and 3), the 
patients in Group 3 who had an elevated follow up LSM value had a 
significantly higher incidence of HCC than those in Group 1 (2.05% [2 of 34 
patients] vs. 0.44% [7 of 598 patients] per 1 person-year, P<0.001), whereas in 
the patients with an initial LSM value >13 kPa (Groups 2 and 4), patients in 
Group 2 who had a decreased follow up LSM value had a significantly lower 
incidence of HCC than those in Group 4 (1.96% [3 of 71 patients] per 1 
person-year vs. 4.31% [14 of 119 patients] per 1 person-year, P<0.001) (Figure 
5). The chi-square test (Fisher's exact test) revealed that the overall incidence of 
HCC differed significantly among four groups (P<0.001).  
 
7. The incidence of liver-related complications  
 
During the follow up period, liver-related complications developed in 40 
patients (3.5%) (variceal bleeding in 27 patients, hepatic encephalopathy in 
eight, and ascites in five). The stratified LSM was significant only in the 
univariate analysis (P=0.045). 
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Figure 4. The incidence rates of HCC in patients assessed for liver cirrhosis 
based on LSM value and clinical criteria at enrollment (n=1,110). 
 
Figure 5. The incidence rates of HCC according to LSM change (n=822). 
 
19 
IV. DISCUSSION 
 
A recent study conducted in Japan proved that LSM predicts HCC development 
in patients with CHC.13 With same hypothesis, our study investigated the 
relationship between LSM and HCC development in patients with CHB, 
although a significant difference in hepatocarcinogenesis exists between HBV- 
and HCV-related HCC. HCV-related HCC occurs mostly in the presence of 
cirrhosis, whereas HBV-related HCC can develop in non-cirrhotic livers, 
although a strong association between HBV-related HCC and cirrhosis has been 
found.25 Despite these different carcinogenetic mechanisms, the usefulness of 
LSM as a predictor of HCC development in patients with CHB was proved in 
our study. 
The rate of unreliable LSM was much lower in our study (2.2%) than that of 
a recent European study.26 Lower BMI and LSM by a single experienced 
operator might explain this result. Previous studies have reported the annual 
incidence of HCC in patients with CHB as 0.5–1%, and 2% in those with 
cirrhosis.2,4,27 By contrast, the incidence of HCC in our study was 2% per 1 
person-year. These results can be explained in several ways. First, because our 
investigation was based in an urban tertiary teaching hospital, the incidence of 
HCC might have been overestimated and the proportion of advanced liver 
disease might be higher than general population of HBsAg bearers. Second, our 
active surveillance (every 3~6 months with ultrasound and AFP) might be 
another explanation. Indeed, among the 57 patients with HCC who were 
detected during surveillance, more than 70% of the patients were operable. On 
the contrary, the incidence of HCC derived from cirrhosis was lower in our 
study when compared with previous studies (49.1% vs. 70~85%).25,28 Although 
the exact reason is not clear, the limited follow-up period of our study might 
underestimate HCC development from the cirrhotic liver. 
Multivariate analysis identified older age, male gender, heavy alcohol 
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consumption, lower serum albumin, HBeAg positivity, and a high LSM value 
as independent predictors of HCC development. All these risk factors were 
similar to those described previously.29-31 However, in contrast to other reports, 
our investigations did not identify ALT and detectable HBV DNA as 
independent predictors of HCC.4,32 As our exclusion criteria included high risk 
patients with elevated ALT (>5× the upper limit of normal [ULN]), the overall 
risk of HCC development in our population may have been lowered. In addition, 
the initiation of antiviral treatment during the study period may have reduced 
the incidence of HCC. Although the exclusion of patients with high ALT may 
result in selection bias, it was necessary to enhance the reliability of LSM.18,33 
In addition, our data did not identify cLC as an independent predictor of HCC 
development, which is the most important risk factor of HCC development. We 
believe that the close correlation between cLC and LSM lessened the influence 
of cLC in the multivariate analysis. This suggests that LSM may be a stronger 
predictor of HCC than cLC.  
When we divided our study population into five groups using the stratified 
LSM value, the proportion of patients with cLC and HCC development 
increased significantly in the groups with high LSM values. Furthermore, the 
stratified LSM value was independently associated with HCC development in 
our study. These results mean that a correlation between high LSM values and 
HBV-related HCC development still remained significant, even if HBV-related 
HCC can develop from a non-cirrhotic background. However, the hazard ratio 
of HCC development in our patients with CHB was lower than that reported for 
those with CHC.13 Indeed, the hazard ratio for HCC development was 45.5 in 
patients who had CHC with LSM value >25 kPa whereas it was only 6.6 in 
patients having CHB with LSM value >23 kPa in our study. The hazard ratio for 
HCC development in our patients may be reduced by HCC cases arising in a 
non-cirrhotic background. However, as liver cirrhosis defined by LSM value 
has been identified as a strong independent risk factor for HBV-related HCC 
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development as in HCV-related HCC,4,25 we cautiously suggest that LSM can 
be used as a predictor of HCC development in both HBV and HCV-related 
CLD. In addition, because 8 kPa has been reported as a cutoff value for 
significant fibrosis (≥F2)22,34, our results suggest that patients with significant 
fibrosis are also at a higher risk of HCC development. 
When the incidence of HCC was compared among groups classified using 
the LSM value and clinical criteria of liver cirrhosis, the incidence of HCC did 
not differ significantly between patients with LSM ≤13 kPa and cLC and those 
with LSM ≤13 kPa and without cLC (Figure 4). However, the mean LSM 
values in patients with LSM ≤13 kPa and cLC was significantly higher than that 
in those with LSM ≤13 kPa and without cLC (9.5 vs. 6.9 kPa, P<0.001). When 
compared with patients with LSM >13 kPa and cLC, the proportions of HBeAg 
positivity (22.2% [n=10] vs. 47.0% [n=62]; P=0.004) and detectable 
HBV-DNA (28.9% [n=13] vs. 43.2% [n=57]; P=0.048) were significantly lower 
in those with LSM ≤ 13 kPa and cLC. Furthermore, most patients (n=35, 
77.8%) had a previous or ongoing use of antiviral agent. Thus, the high 
proportion of antiviral treatment, lower rate of HBeAg positivity and detectable 
HBV DNA might have led to completely inactive cirrhosis or resolving 
fibrosis.35 This hypothesis might explain the similar incidence of HCC between 
patients with LSM ≤13 kPa and cLC and those with LSM ≤13 kPa and without 
cLC. 
When we compared two groups with discordance in the diagnosis of 
cirrhosis by LSM and clinical criteria, the incidence rates of HCC were higher 
in patients with LSM >13 kPa and no cLC than in those with LSM ≤13 kPa and 
cLC (Figure 4), which might propose the possibility that patients with early 
compensated liver cirrhosis might have been misstratified as having CHB 
according to clinical criteria. Finally, when the diagnosis of liver cirrhosis was 
made by clinical criteria and LSM simultaneously, the incidence of HCC was 
the highest (5.84% person-year). All these results suggest that LSM might be 
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more reliable method for diagnosis of compensated liver cirrhosis than clinical 
criteria, and that LSM can identify the optimal time to recall surveillance 
program for these high risk patients with compensated liver cirrhosis. 
Importantly, although the performance of LSM for the prediction of early 
compensated liver cirrhosis in cross-sectional studies has already been 
investigated,20,36 this is the first study to suggest the usefulness of LSM in 
diagnosis of early compensated liver cirrhosis in a prospective and longitudinal 
setting by investigating a clinical end-point, defined as the risk of HCC 
development. 
Interestingly, the overall incidence of HCC differed significantly according 
to the LSM change (Figure 5). These results suggest that serial measurements 
of the LSM value can be used as a dynamic indicator of the risk of HCC 
development; these findings are supported by previous studies.37 The incidence 
of liver-related complications was investigated further. However, the stratified 
LSM was not significant in the multivariate analysis. However, because the 
number of HCC development and liver-related complication seems to be still 
small in our study, confirmative longitudinal observation studies should be 
followed. 
We are aware of the limitations of our study. One major unamendable 
limitation was the absence of LB data at enrollment. Thus, the exact status of 
background liver was not informed and we could not provide additional 
information on the performance of LSM in predicting HCC development in 
comparison with LB. Another limitation is the method with low sensitivity we 
used to assess the serum HBV-DNA, which caused difficulties in estimating the 
association between the serum HBV-DNA level and HCC development and in 
characterizing our study population completely from inactive carriers to active 
hepatitis. Third, the relatively short follow-up period can be also one of our 
limitations. Thus, the role of LSM as a predictor of HCC development in 
patients with CHB should be confirmed in the future through subsequent studies 
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with a long-term follow-up period. Lastly, our results can only be applied to a 
subpopulation of patients with CHB showing limited ALT level (≤5x ULN).33,38 
However, when ALT levels subside after active antiviral treatment in patients 
with elevated ALT, the reliability of LSM may be restored as indicated in the 
previous study38 and LSM may be used as a significant predictor of HCC 
development. 
 
V. CONCLUSION 
 
In conclusion, this prospective cohort study showed a significant association 
between LSM and the risk of HCC development in patients with CHB. 
Therefore, LSM can be used as a noninvasive predictor of HCC development in 
these patients. Further research is needed to confirm whether surveillance 
program for HCC in patients with CLD should be adjusted according to LSM. 
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ABSTRACT(IN KOREAN) 
만성 B형 간염 환자에서 Liver stiffness measurement 
(FibroScan®)를 통한 간세포암의 발생 위험도 평가 
 
<지도교수 : 한 광 협> 
 
연세대학교 대학원 의학과 
 
성    명: 정 규 식 
 
 
 
서론: FibroScan®을 이용한 Liver stiffness measurement (LSM)는 만성 C형 
간염 환자에서 간섬유화의 정도를 정확히 평가할 뿐 만 아니라, 
간세포암 발생의 위험도를 평가하는데도 유용하게 사용 될 수 있다는 
것이 최근의 연구에서 보고되었다. 본 연구의 목적은 만성 B형 간염 
환자에게서 LSM이 간세포암 발생의 예측인자로 사용될 수 있는지 
조사하는 것이다.  
 
재료 및 방법: 2005년 5월부터 2007년 12월까지 총 1130명의 만성 B형 
간염 환자가 본 연구에 등록되었다. 등록 후 LSM을 시행하였으며, 
이후 주기적으로 간세포암에 대한 검진 검사를 시행하며 추적 
관찰하였다.  
 
결과: 전체 환자군의 평균 나이는 50.2 ± 9.9세 였으며, 평균 LSM 
수치는 10.3 ± 8.4 kPa 이였다 (남성 767명, 여성 363명). 연구기간 
전후로 672명의 환자(59.5%)는 항바이러스 치료를 받았다. 추적 관찰 
기간 동안 (중앙값 30.7 개월; 범위 24-50.9 개월) 간세포 암은 57 
명에서 발생하였으며, 간세포암 발생률은 1인년 당 2.0%였다. 추적 
관찰 중 1, 2, 3년의 간세포암의 누적 발생률은 각각 0.80%, 3.26%, 
5.98%이었다. 다변량 분석에서, 고령, 남성, 알코올 섭취 80g 이상, 
혈중 albumin 농도, HBeAg 양성과 함께 높은 LSM 수치가 
통계학적으로 유의한 간세포암 발생의 위험인자로 확인되었다. LSM 
30 
수치가 8 kPa 이하인 환자군과 비교하여, 8 kPa 초과하고 13 kPa 
이하인 환자군의 경우는 3.07의 상대위험도를 가진 것으로 
평가되었으며 (95% 신뢰구간, 1.01–9.31; P=0.047), 13 kPa 초과하고 18 
kPa 이하인 경우에는 4.68의 상대위험도를 가지는 것으로 (95% 
신뢰구간, 1.40–15.64; P=0.012), 18 kPa 초과하고 23 kPa 이하인 
경우에는 5.55의 상대위험도를 가지는 것으로 (95% 신뢰구간, 
1.53–20.04; P=0.009), 23 kPa 초과하는 경우에는 6.60 의 상대위험도를 
가지는 것으로 평가되었다 (95 % 신뢰구간, 1.83–23.84; P=0.004). 
 
결론: 본 연구를 통하여 만성 B형 간염 환자에 있어, LSM이 
간세포암의 예측인자로서 사용 될 수 있음을 확인하였다. 
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